PureTech Health (LON:PRTC) Trading Down 15.2% – What’s Next?

PureTech Health plc (LON:PRTC)’s stock price dropped 15.2% during trading on Wednesday . The stock traded as low as GBX 117.20 ($1.52) and last traded at GBX 117.20 ($1.52). Approximately 42,764,352 shares changed hands during mid-day trading, an increase of 2,645% from the average daily volume of 1,557,904 shares. The stock had previously closed at GBX 138.20 ($1.79).

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group reiterated a “buy” rating and set a GBX 455 ($5.91) target price on shares of PureTech Health in a research report on Monday, December 16th.

PureTech Health Trading Up 11.7 %

The stock has a 50 day moving average of GBX 135.83 and a 200-day moving average of GBX 148.25. The company has a market capitalization of £345.50 million, a P/E ratio of -4.72 and a beta of 1.02. The company has a current ratio of 3.68, a quick ratio of 2.51 and a debt-to-equity ratio of 45.82.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.